Answers are grounded in this paper and cite their sources.
This study provides Class III evidence that alemtuzumab provides efficacy and slowing of brain atrophy through 5 years.
No takes yet. Share an insight, caveat, or question.
Coles et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: